John Andrew Livingston, MD, MS, discusses responses with gemcitabine, docetaxel, and hydroxychloroquine in advanced, metastatic osteosarcoma.
John A. Livingston, MD, MS
Advertisement
John A. Livingston, MD, MS, is a clinician and researcher in the Department of Sarcoma Medical Oncology, of the Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center.
Articles by John A. Livingston, MD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5